UNIVERSITY COLLEGE LONDON

Vesper Bio's VES001 demonstrated a greater than 95% mean increase in cerebrospinal fluid progranulin levels compared to baseline in asymptomatic carriers with FTD-GRN mutations.

The EJS ACT-PD platform represents the first multi-arm, multi-stage clinical trial for Parkinson's disease in the UK, designed to test multiple treatments simultaneously against a shared placebo group.

Experimental gene therapy restored immune function in 59 of 62 children with ADA-SCID, achieving 100% overall survival and 95% event-free survival over a mean follow-up of 7.5 years.

Post hoc analysis of pooled BOREAS and NOTUS phase 3 trials demonstrates dupilumab's consistent efficacy in reducing COPD exacerbations by 31-33% regardless of cardiovascular or metabolic disease history.

Researchers at University College London have successfully treated Huntington's disease for the first time using gene therapy AMT-130, achieving a 75% reduction in disease progression after three years.

Eisai's investigational anti-MTBR tau antibody etalanetug (E2814) has been granted FDA Fast Track designation to expedite development for Alzheimer's disease treatment.

The PRIME trial demonstrated that biparametric MRI was noninferior to multiparametric MRI in detecting clinically significant prostate cancer, with detection rates of 29.2% versus 29.6% respectively.

A large UK retrospective study of 624,308 adults found that metformin initiated within 90 days of COVID-19 infection reduced Long COVID risk by 64% in overweight or obese individuals.

Upperton Pharma Solutions has secured funding from the VaxHub Sustainable Platform Funding Call to develop an oral formulation for adenovirus-vectored vaccines in collaboration with the University of Oxford.

Qualigen Therapeutics has been granted new patents covering QN-302, a cancer drug candidate targeting pancreatic and gastrointestinal cancers, across more than 25 countries including over 20 European nations, India, China, and Russia.